VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2021 | Trial updates in prostate cancer from ASCO 2021: VISION, PEACE1, & SWOG S1216

Pedro Barata, MD, MSc, Tulane University School of Medicine, New Orleans, LA, gives an overview of the major highlights in the prostate cancer field from ASCO 2021. Several large-scale Phase III trials in the advanced prostate cancer setting were presented at this year’s meeting. Dr Barata comments on the much-anticipated results of the VISION trial (NCT03511664) assessing the addition of 177Lu-PSMA-617 to standard of care (SOC) in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The trial was the first to demonstrate a statistically significant improvement in overall survival with a PSMA-targeted agent in this patient population and may be practice-changing. Dr Barata also discusses the implications of the first results from the Phase III PEACE-1 trial (NCT01957436) of abiraterone combined with SOC with or without local radiotherapy in men with mCRPC. The PEACE III (NCT02194842) trial assessing the upfront combination of enzalutamide and radium-223, and the SWOG S1216 trial (NCT01809691) of androgen deprivation therapy plus TAK-700 are also highlighted. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter